Mentions
Extended reach
Total likes
Video views
AI synopsis
Several mentions, such as the posts describing Orforglipron as a 'game-changing' oral GLP-1 receptor agonist, demonstrate high interest and engagement through detailed discussion of trial data and treatment implications. The tone is optimistic, emphasizing the drug's efficacy (HbA1c reductions up to -1.48%), safety profile, and ease of use, indicating a strong belief in its high impact for diabetes management.
Most mentions acknowledge the positive findings of the phase 3 trial, highlighting its significance.
Mentions use enthusiastic language like 'promising results' and emphasize the potential of a new oral medication, indicating high interest.
Many mentions discuss detailed trial results, safety, and implications, showing deep engagement.
Mentions consistently highlight the potential for major advances in diabetes treatment and medication accessibility, indicating significant impact.
★2025年糖尿病領域キー論文まとめ★ 今年発表された糖尿病関連論文のうち、知っていてほしい27本についてまとめました！（糖尿病メモ新着論文集の★３つ論文です） ① チルゼパチド、CVD抑制でデュラグルチドに優越性示せず SURPASS-CVOT試験。 2型DM・心血管疾患既往例13,165人を対象とした国際共同第3相RCT。 チルゼパチド（最大15mg/週）とデュラグルチド（1.5mg/週）を比較し、MACEはHR 0.92（0.83–1.01）。 非劣性は示されたが、優越性は示されなかった（P=0.09）。 Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409–2420. ② 経口セマグルチドが心血管イベント抑制 SOUL試験。 CVDまたはCKD合併2型DM 9,650人、約4年間のRCT。 経口セマグルチド14mgで複合CVDはHR 0.86（0.77–0.96）。 心筋梗塞HR 0.73、全死亡HR 0.91、消化器系有害事象は5.0% vs 4.4%。 McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. ③ 経口GLP-1オルフォルグリプロン、早期2型糖尿病への効果 ACHIEVE-1試験。 食事運動療法のみの2型DM 559人、40週間。 HbA1cは−0.83〜−1.07%、体重は−4.5〜−7.6%。 主な副作用は軽度〜中等度の消化器症状。 Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N E
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://t.co/qKRfQon3fN Editorial: Mimicking Complex Receptor Actions with Small(ish) Molecules https://t.co/551PZYPm9D #Endocrinology https://t.co/bMCdIt6jS6
? New in @NEJM : Orforglipron, a once-daily oral GLP‑1, led to ~2% A1c drop & ~16 lb weight loss in T2D (ACHIEVE-1 trial). A non-peptide, no-injection option with classic GLP-1 GI profile. Big step for access & adherence! ?https://t.co/aIb2CShopY
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://t.co/qKRfQon3fN @ADA_DiabetesPro | #ADASciSessions https://t.co/TlSPkixnBI
The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | @NEJM https://t.co/9XuyCeT6ew
✍️ Here comes Orforglipron- the Oral GLP-1 Receptor Agonist for Type 2 Diabetes ✍️ I hope it also works like Ozempic for weight loss ✍️Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/ClMHeBhcrX?
Foundayo (orforglipron) is the first truly convenient GLP-1 weight loss pill — once daily, no food or water rules, and no injections. Dr. Zaid Fadul explains how it works, real results, side effects, dosing, cost, and…
Un medicamento tipo GLP-1 en una pastilla y sin necesidad de inyecciones? Orforgliprón is an oral GLP-1 receptor agonist studied in a phase 3 trial with 559 adults. Results show significant HbA1c and weight reductions…
How will health care evolve by 2026? This video explores advancements such as AI-driven personal health coaching, oral GLP-1 pills for weight loss, developments in cancer vaccines, and the rise of longevity science…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 40 weeks in a phase 3 trial involving 559 participants with type 2 diabetes, showing significant reductions in glycated hemoglobin levels…
Orforglipron: A Diabetes Game Changer Hidden in Plain Sight. Unpack the latest data on this once-daily oral GLP-1 receptor agonist from the ACHIEVE-1 trial, which demonstrated significant HbA1c reductions of up to 1.5%…
¿El fin de las inyecciones de GLP-1? Análisis a fondo del ensayo ACHIEVE-1 (Orforgliprón) que evalúa el primer agonista oral del receptor GLP-1 de molécula pequeña. Este estudio muestra la eficacia en reducir HbA1c y…
Orforglipron, Eli Lilly’s new oral, non-peptide GLP-1 receptor agonist, was tested over 40 weeks in a phase 3 trial involving 559 participants with type 2 diabetes, showing significant reductions in glycated hemoglobin…
Diabetes Core Update discusses the latest research, including a phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist. Results show significant HbA1c reductions over 40 weeks, highlighting its potential for…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 40 weeks in a phase 3 trial involving 559 participants with type 2 diabetes. The study showed significant reductions in glycated hemoglobin…
ACHIEVE-1: Phase 3 Trial of Orforglipron for Type 2 Diabetes details the efficacy and safety of this oral, once-daily GLP-1 receptor agonist. Involving 559 participants over 40 weeks, the drug significantly reduced…
Since 2025, diabetes medications have evolved from solely lowering blood glucose to protecting organs. This overview covers key clinical trials on oral GLP-1 receptor agonists, weekly insulins, and disease-modifying…
Orforglipron, a novel oral small-molecule GLP-1 receptor agonist, was tested over 40 weeks in a phase 3 trial involving 559 participants with type 2 diabetes, showing significant reductions in glycated hemoglobin levels…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, was tested over 40 weeks in a phase 3 trial involving 559 participants with type 2 diabetes, showing significant reductions in glycated hemoglobin levels…
Orforglipron—an oral small-molecule GLP-1 receptor agonist in trials—shows promising results in reducing HbA1c in type 2 diabetes patients. This PubMed-cited review discusses current research findings, emphasizing…
Orforglipron (Foundayo) is an oral, non-peptide small-molecule partial agonist at the GLP-1 receptor, enabling easy daily dosing without injections. In phase 3 trials, it significantly reduced body weight and improved…
Orforglipron, a novel oral small-molecule GLP-1 receptor agonist, was tested over 40 weeks in a phase 3 trial involving 559 participants with type 2 diabetes. It demonstrated significant reductions in glycated…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/2TksocbB58 The therapies are getting better and better. Small molecule drugs are coming. I expect to see similar medications for obesity soon!
#foundayo #glp1 #orforglipron #elilly https://t.co/OQciSLnopa
In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes. Download the Notable Articles of 2025: nej.md/49td1Lq
★2025年糖尿病領域キー論文まとめ★ 今年発表された糖尿病関連論文のうち、知っていてほしい27本についてまとめました！（糖尿病メモ新着論文集の★３つ論文です） ① チルゼパチド、CVD抑制でデュラグルチドに優越性示せず SURPASS-CVOT試験。 2型DM・心血管疾患既往例13,165人を対象とした国際共同第3相RCT。 チルゼパチド（最大15mg/週）とデュラグルチド（1.5mg/週）を比較し、MACEはHR 0.92（0.83–1.01）。 非劣性は示されたが、優越性は示されなかった（P=0.09）。 Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409–2420. ② 経口セマグルチドが心血管イベント抑制 SOUL試験。 CVDまたはCKD合併2型DM 9,650人、約4年間のRCT。 経口セマグルチド14mgで複合CVDはHR 0.86（0.77–0.96）。 心筋梗塞HR 0.73、全死亡HR 0.91、消化器系有害事象は5.0% vs 4.4%。 McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. ③ 経口GLP-1オルフォルグリプロン、早期2型糖尿病への効果 ACHIEVE-1試験。 食事運動療法のみの2型DM 559人、40週間。 HbA1cは−0.83〜−1.07%、体重は−4.5〜−7.6%。 主な副作用は軽度〜中等度の消化器症状。 Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N E
2026'da sağlık teknolojilerinde neler değişecek dersiniz? Videonun tamamı YouTube kanalımızda. Gelin birlikte 2026'da sağlıkta neler değişecek göz atalım. https://t.co/vgpzJ9Ffao #saglik #saglikteknolojileri #sağlıkhaberleri https://t.co/ESBOAf2ZT8
2026 sağlık dünyası nasıl olacak? Yapay zekâ kişisel sağlık koçuna mı dönüşüyor? Zayıflama iğneleri yerini haplara mı bırakacak? Obezite cerrahisi azalacak mı? Kanser aşıları gerçekten yakın mı? Longevity neden yükselişte? https://t.co/4KPS9kyDkk #saglik #saglikhaberleri https://t.co/iS0u3qlZ45
https://t.co/4BkvzpcDxm
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Another “miracle” weight-loss drug is in the pipeline: Orforglipron. ? In 10 months, it lowered glycated hemoglobin HbA1c from ~8% → 6.5–6.7%. ⚠️ Reminder: anything >6.4% is still diabetes! ❌ Adverse events forced discontinuation in 4.4–7.8% of patients. Meanwhile, a ketogenic diet + fasting can push HbA1c below 6% in just 3-6 months — without new side-effect labels. DOI: 10.1056/NEJMoa2505669
✍️ Here comes Orforglipron- the Oral GLP-1 Receptor Agonist for Type 2 Diabetes ✍️ I hope it also works like Ozempic for weight loss ✍️Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/ClMHeBhcrX?
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes https://t.co/2WSEGDw625
In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes. Full trial results and Research Summary: nej.md/4ngEZ36 #MedSky #EndoSky
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @DrKarlNadolsky: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Obesity + Early Type 2 Diabetes | NEJM -1.5% HbA1c redu…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://t.co/qKRfQon3fN Editorial: Mimicking Complex Receptor Actions with Small(ish) Molecules https://t.co/551PZYPm9D #Endocrinology https://t.co/bMCdIt6jS6
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/mziedF67IE
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Obesity + Early Type 2 Diabetes | NEJM -1.5% HbA1c reduction & 6-7.6% weight loss vs -0.4% and -1.7% resp for placebo https://t.co/SCPOVNMJZf
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.”” Publié ce jour dans le @nejm.org. #MedSky #EndoSky www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes https://t.co/rhAtIy1FZL
? "Ozempic" v pilulce? Nový lék bez jehel pomáhá s cukrovkou i hubnutím. Podle ?? studie publikované v časopise @NEJM lék orforglipron ukazuje slibné výsledky již po 40 týdnech léčby. Více v našem článku: https://t.co/GuoLHWCutX Zdroj: Rosenstock, J., Hsia, S., Ruiz, L. N., Eyde, S., Cox, D., Wu, W., Liu, R., Li, J., Landó, L. F., Denning, M., Ludwig, L., & Chen, Y. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine.
? Ya disponibles los datos de Fase 3 sobre hemoglobina glicosilada de #Orforglipron ?¿Qué es? Un agonista del receptor GLP-1 oral en desarrollo clínico para la diabetes tipo 2 y el control del peso. ?Resultados tras 40 semanas: • Reducción de HbA1c de hasta –1.48% • Pérdida de peso de hasta –7.6% • Sin hipoglucemias graves • Perfil de seguridad favorable DOI: 10.1056/NEJMoa2505669
The second @nejm.org #orforpligron paper is out. There is no doubt that Oral GLP-1s are coming. For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) which always seems higher. How might our patients fare? #liversky
The second @NEJM #orforpligron paper is out. There is no doubt that Oral GLP-1s are coming. For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) How might our patients fare? #livertwitter https://t.co/1aUMBnZk6n
? Ya disponibles los datos de Fase 3 sobre hemoglobina glicosilada de #Orforglipron ?¿Qué es? Un agonista del receptor GLP-1 oral en desarrollo clínico para la diabetes tipo 2 y el control del peso. ?Resultados tras 40 semanas: • Reducción de HbA1c de hasta –1.48% • Pérdida de peso de hasta –7.6% • Sin hipoglucemias graves • Perfil de seguridad favorable DOI: 10.1056/NEJMoa2505669
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. The New England journal of medicine, 10.1056/NEJMoa2505669. https://t.co/hNLokpG2gU
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Orforglipron is a small-molecule,…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Orforglipron is a small-molecule,…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Orforglipron is a small-molecule,…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed. In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks https://t.co/nM7ohohS28
【RCT】HbA1c7.0%-9.5%でBMIが23以上の食事療法と運動療法のみの2型糖尿病患者へのOrforglipronの投与は、プラセボの投与と比較して、HbA1cを減少させた。 #ペ読 https://t.co/JH7g0ONKuJ
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/roQkCN3p7y
A clinical trial found that orforglipron, a new medication for type 2 diabetes, significantly lowered blood sugar levels and helped participants lose weight over 40 weeks, with mild digestive side effects being common. - Read more: https://t.co/IbxS28KsJy
A 40-week study found that orforglipron, a new medication for type 2 diabetes, significantly lowered blood sugar levels and aided weight loss in participants compared to a placebo, with manageable side effects. - Read more: https://t.co/IbxS28KsJy
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Acceso artículo en @PubMedOnline https://t.co/RmgV8bfdJv
Acceso en #pubmed pubmed.ncbi.nlm.nih.gov/40544435/
Full text links www.nejm.org/doi/10.1056/...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/Rjju295cKZ
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/TWxcEXu3mi
@annakrook.bsky.social I found this www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes #science #publication #research #journal https://t.co/vtK9OdIsA7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/BDibuWZ1Y5
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Introducing Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early #T2D! ? ACHIEVE-1 trial investigators report that in adults with early T2D, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. @NEJM | https://t.co/dBfeGZ97c8
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/np3ThAVRtP
This could mark a major step forward in oral GLP-1 therapies for type 2 diabetes. manuscript: www.nejm.org/doi/full/10.... #Diabetes #GLP1 #Orforglipron #WeightManagement #Endocrinology #ClinicalTrials
? Latest in Type 2 Diabetes & Weight Management ? New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @CristobMorales: https://t.co/YwCnsjilp4 Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New Eng…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes #science #publication #research #publications https://t.co/XWlEm6VyMP
RT @KSusztak: The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | @NEJM https://t.co…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes In adults with early type 2 diabe…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks https://t.co/EjiiorKHAX https://t.co/2qDK3nulnZ
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks https://t.co/EjiiorLfqv https://t.co/5zitcyAKOj
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @KSusztak: The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | @NEJM https://t.co…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @KSusztak: The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | @NEJM https://t.co…
RT @KSusztak: The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | @NEJM https://t.co…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @CristobMorales: https://t.co/YwCnsjilp4 Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New Eng…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)…
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://t.co/qKRfQon3fN @ADA_DiabetesPro | #ADASciSessions https://t.co/TlSPkixnBI
The oral GLP !! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | @NEJM https://t.co/9XuyCeT6ew
www.nejm.org/doi/full/10....
RT @CMEINDIA1: Key clinical pearls from the ACHIEVE-1 trial on Orforglipron (NEJM 2025; DOI:10.1056/NEJMoa2505669): ? ORFORGLIPRON – Oral…
RT @CMEINDIA1: Key clinical pearls from the ACHIEVE-1 trial on Orforglipron (NEJM 2025; DOI:10.1056/NEJMoa2505669): ? ORFORGLIPRON – Oral…
Key clinical pearls from the ACHIEVE-1 trial on Orforglipron (NEJM 2025; DOI:10.1056/NEJMoa2505669): ? ORFORGLIPRON – Oral Nonpeptide GLP-1 RA ? Once-daily oral GLP-1 agonist (non-peptide) ? First-in-class, no fasting or water restrictions ? ACHIEVE-1 Trial Highlights (40 Weeks) ? 559 adults with early T2DM (HbA1c 7–9.5%, BMI ≥23) ? Orforglipron 3/12/36 mg vs placebo ✅ HbA1c Reduction • −1.24% (3 mg) • −1.47% (12 mg) • −1.48% (36 mg) • Placebo: −0.41% ✅ Weight Loss • −4.5% (3 mg) • −5.8% (12 mg) • −7.6% (36 mg) • Placebo: −1.7% ⚠️ Safety Profile ? GI AEs (mild-moderate): nausea, diarrhea ? No severe hypoglycemia ? Discontinuation: 4–8% (vs 1.4% placebo) ? CME INDIA Pearls ? Oral GLP-1RA = injectable-like efficacy with better convenience ? HbA1c <6.5% achieved in majority at 36 mg ? Excellent weight loss (~7–8%) without plateau at 40 weeks ? Ideal for early T2DM, obese, needle-a
Orforglipron, small molecule GLP-1ra in type 2 #diabetes. ➡️mean HbA1c at baseline was 8.0%. At week 40, it dropped −1.24% with 3-mg, −1.47 % with 12-mg, −1.48 % with 36-mg dose, and −0.41 % with placebo. www.nejm.org/doi/full/10.... #ADA2025
RT @CristobMorales: https://t.co/YwCnsjilp4 Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New Eng…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/BDibuWZ1Y5
¿Un GLP-1 oral, sin restricciones ni aguja, con eficacia comparable a inyectables? Orforglipron es el primer agonista del receptor GLP-1 no peptídico aprobado en estudios fase 3 para la diabetes tipo 2. Su principal ventaja: se administra en cápsula diaria, sin restricciones de comida, agua o ayuno. Publicado en NEJM el 21 de junio de 2025 (DOI: 10.1056/NEJMoa2505669), el estudio ACHIEVE-1 evaluó su eficacia y seguridad en 559 adultos con diabetes tipo 2 temprana manejada solo con dieta y ejercicio. – Diseño doble ciego, controlado con placebo – Tres dosis (3, 12 y 36 mg/día) por 40 semanas – Sin uso previo de fármacos antidiabéticos Resultados clave: – Reducción de HbA1c hasta –1.48 % – Reducción de peso corporal de hasta –7.9 % – HbA1c < 7 % en 76.2 % – HbA1c ≤ 6.5 % en 66.0 % – HbA1c < 5.7 % (valor normal) en 25.8 % – Efecto sostenido desde semana 4 Ventajas farmacológicas: – Vida
? New in @NEJM : Orforglipron, a once-daily oral GLP‑1, led to ~2% A1c drop & ~16 lb weight loss in T2D (ACHIEVE-1 trial). A non-peptide, no-injection option with classic GLP-1 GI profile. Big step for access & adherence! ?https://t.co/aIb2CShopY
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early T2DM | New England Journal of Medicine. phase 3, double-blind, placebo-controlled trial, randomly assigned in a 1:1:1:1 ratio to receive orforglipron at 1 of 3 doses (3 mg, 12 mg, 36 mg) https://t.co/yXChehuZpu
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine https://t.co/e4V0UJkOfW
https://t.co/YwCnsjilp4 Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine @NEJM #ADA2025
A detailed P3 look at the leading small molecule oral GLP-1 RA orforglipron studied at a range of doses for moderate #T2D Good tolerability, solid efficacy on glucose and #weightloss no serious off target SAEs www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N. Engl. J. Med.; 2025; 393, pp. 1065-1076. [DOI: https://dx.doi.org ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in adults with obesity. N Engl J Med. 2025;393:1796–1806. doi:10.1056/NEJMoa2511774. Aljazeeri ...
"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes". New England Journal of Medicine. 393 (11). doi:10.1056 ...
J Rosenstock et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. (2025). DJ Drucker. GLP-1-based ...
J Rosenstock et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. (2025). DJ Drucker. GLP-1-based ...
Source Citation. Rosenstock J, Hsia S, Nevarez Ruiz L, et al; ACHIEVE-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in ...
. 10.1056/NEJMoa2505669. Pubmed Abstract · CrossRef · Google Scholar; View reference in article. 23. SchellingJ. R. (2022). The contribution of lipotoxicity to ...
This article was published on September. 16, 2025, at NEJM.org. DOI: 10.1056/NEJMoa2511774. Copyright © 2025 Massachusetts Medical Society. BACKGROUND.
, 10.1056/NEJMoa2505669 · View in Scopus Google Scholar. Selby and Zawertailo, 2022. P. Selby, L. Zawertailo. Tobacco Addiction. The New England Journal of ...
10.1056/NEJMoa2505669. [Preprint]. Crossref View in Scopus Google Scholar. 44. J. Shang, F. Liu, B. Zhang, K. Dong, M. Lu. Liraglutide-induced structural ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes 2. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without ...
https://doi.org/10.1056/NEJMoa2505669. 5. Gleason, P.P.; Urick, B.Y.; Marshall, L.Z.; et al. Real-world persistence and adherence to glucagon-like peptide-1 ...
doi:10.1056/NEJMoa2505669. International Conference on Harmonisation. Ethnic factors in the acceptability of foreign clinical data (ICH E5 R1). Geneva: ICH; ...
DOI: 10.1056/NEJMoa2505669. original sound - kivxr · Para Que Sirve Gestrygen · Texapon Para Que Sirve · Para Que Sirve Exicort Etoricoxib · Indigon Para Que ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025; 393:1065-1076. doi:10.1056/NEJMoa2505669. 1 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025; 393(11):1065-1076. doi:10.1056/NEJMoa2505669 ℹ️ ...
https://doi.org/10.1056/NEJMoa2505669 #Metabolife #Orforglipron #Obesidad #DiabetesTipo2 #SaludMetabólica #GLP1 · May be an image of medicine and text.
doi:10.1056/ cagrilintide and semaglutide in adults with 21. Linge J ... 2025.01. 1126/science.adn4128 NEJMoa2505669 019. 7. Jastreboff AM, Kaplan LM ...
NEJM: "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes." View privacy policy, copyright and trust info. Share. Print.
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
N Engl J Med. 2025. doi:10.1056/NEJMoa2505669. September 2 · dr.fernando.costa's profile picture · dr.fernando.costa. •. Follow. AI content.
10.1056/NEJMoa2505669; Frias JP, Hsia S, Eyde S, et al.: Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a ...
... 10.1056/NEJMoa2505669. |. what-does-lamed-in-creole-mean. |. المسلسل الصيني حتى اراك. |. La politesse peut-elle résoudre n'importe quelle ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes" . ผลการศึกษา จากผู้เข้าร่วมทั้งหมด 559 คน เป็นผู้ ...
org/doi/full/10.1056/NEJMoa2505669 . #Orforglipron #เบาหวาน #ยาลดน้ำหนัก #หมอยาเพ้อเจ้อ ⚕️ · No photo description available. Duangrudee ...
... 10.1056/NEJMoa2511774. Rosenstock J et al. N Engl J Med. 2025;393:1065–1076. DOI: 10.1056/NEJMoa2505669. Aronne LJ et al. Nature Medicine ...
https://doi.org/10.1056/NEJMoa2505669 #Metabolife #Orforglipron #Obesidad #DiabetesTipo2 #SaludMetabólica #GLP1. May be an image of medicine ...
En este video te explico rápidamente por qué está llamando tanto la atención y qué deberías saber antes de pensar que “solo es otra pastilla ...
... 10.1056/NEJMoa2505669 ➥ DOI: 10.1056/NEJMoa2505669; M. J. Davies, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and ...
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
1. Recent posts. Alfonso Casi ▻ Salud juntos. Divulgación de salud y viajes. 3y · Public · Agonista oral diario del receptor de ...
DOI: 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #DiabetesTipo2 #HbA1c PérdidaDePeso Obesidad. Recent posts.
DOI: 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #DiabetesTipo2 #HbA1c PérdidaDePeso Obesidad. View all 6 comments · analilia585.
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N. Engl. J. Med. 393, 1065–1076 (2025). Article CAS ...
doi:10.1056/NEJMoa2505669. Contenido educativo dirigido principalmente a profesionales de la salud. No sustituye una valoración médica ...
DOI: 10.1056/NEJMoa2505669 • Aronne LJ, et al. ATTAIN-MAINTAIN. Nature Medicine, 2026. DOI: 10.1038/s41591-026-04386-7. View all 2 comments · 1 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025; 393:1065-1076. doi:10.1056/ ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065-1076. https://www ...
DOI: 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #DiabetesTipo2 #HbA1c ⚖️. sonido original - dr.mikediabetes. 15.8KLikes. 719 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl. J. Med. 2025, 393(11), 1065–1076. [Google ...
DOI: 10.1056/NEJMoa2505669. original sound - kivxr · Alabai Precio En Mexico · Precio De Misoprostol Farmacia Guadalajara · Precio De Quemalip ...
doi: 10.1056/NEJMoa2505669. Epub 2025 Jun 21. PMID: 40544435. * Kotecha P, Huang W, Yeh YY, Narvaez VM, Adirika D, Tang H, Bernier AV ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early molecule is what differentiates it from established agents like ...
Farmaceuticos UCR. 2761 followers · 3 talking about this. Lograr unir a colegas con un fin amistoso y de compartir anécdotas de esta bella ...
... 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #México #GLP1 #DiabetesTipo2 HbA1c PérdidaDePeso | Dr Miguel Angel Rodriguez | Facebook ...
... 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #DiabetesTipo2 #HbA1c PérdidaDePeso Obesidad. Log in. Dr Miguel Angel Rodriguez's post.
⚖️ Bibliografía: Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med ...
... 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #RetinopatíaDiabética #DiabetesTipo2 HbA1c SaludVisual ?️ . Log in. Dr Miguel Angel ...
... 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #DiabetesTipo2 #HbA1c ControlDePeso Obesidad MedicinaBasadaEnEvidencia ⚖️. Log in.
Bibliografía: Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025; ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393:1065-1076. DOI: 10.1056 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Article. Jun 2025; NEW ENGL J MED. Julio ...
... representar na prática clínica. Referência: Wharton S, et al. N Engl J Med. 2025. doi:10.1056/NEJMoa2505669.".
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393:1065-1076. doi:10.1056 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2511774; Wharton ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity. N Engl J Med. 2025. doi: 10.1056/NEJMoa2511774; Wharton ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, in this quick pharmacology review. Learn its ADME, mechanism of action ...
DOI: 10.1056/NEJMoa2505669 #ACHIEVE1 #Orforglipron #GLP1 #RetinopatíaDiabética #DiabetesTipo2 HbA1c SaludVisual ?️ . September 7 · dr ...
N Engl J Med. 2025. doi:10.1056/NEJMoa2505669. September 2 · iasis.dr.leandromarinari's profile picture · iasis.dr.leandromarinari. •. Follow.
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
... 10.1056/NEJMoa2511774 Dr. Filippo Pedrinola CRM 62253-SP | RQE ... doi:10.1056/NEJMoa2505669. September 2 · leticiaalvessm's profile ...
doi:10.1056/NEJMoa2505669. 23. Rosenstock J, Robins DA, Duffin KL, et al. Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor ...
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med 393: 1065–76. Rosenstock J, Yabe D, Cox D ...
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
Nevarez Ruiz, et al., “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes,” New England Journal of ...
DOI: 10.1056/NEJMoa2505669. https://www.nejm.org/doi/full/10.1056/NEJMoa2505669; AJMC. FDA Approves Lilly's Oral GLP-1 Orforglipron for ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025; 393(11):1065-1076. doi:10.1056 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
; et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes . N. Engl. J. Med. 2025. ,. 393. (. 11. ),. 1065.
et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes . N Engl J Med . 2025. ;. 393. : 1065. –. 76.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity. N Engl J Med. 2025. doi: 10.1056/NEJMoa2511774; Wharton ...
... 10.1056/NEJMoa2505669. 6. McGovern G. FDA approves orforglipron, first GLP-1 pill without time, food, or water restrictions. Pharmacy Times ...
doi:10.1056/NEJMoa2505669. Contenido educativo dirigido principalmente a profesionales de la salud. No sustituye una valoración médica ...
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
DOI: 10.1056/NEJMoa2505669. Aronne LJ et al. Nature Medicine. 2026;32:2679–2687. ACHIEVE-3. The Lancet. 2026.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393:1065-1076. doi:10.1056 ...
Orforglipron, an Oral Small- Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine. 6. Lilly ACHIEVE ...
DOI: 10.1056/NEJMoa2505669. Aronne LJ et al. Nature Medicine. 2026;32:2679–2687. ACHIEVE-3. The Lancet. 2026.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
Orforglipron, an oral Small-Molecule GLP-1 receptor Agonist, in early type 2 diabetes. N Engl J Med. 2025;393:1065–76. Article CAS PubMed ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
org/doi/full/10.1056/NEJMoa2505669?log out=true. nejm.org. Orforglipron, an Oral Small- Molecule GLP-1 Receptor Agonist,. 8mo. 母語ê/gǎi醫學.
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi: 10.1056 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
https://doi.org/10.1056/NEJMoa2505669. 5. Gleason, P.P.; Urick, B.Y.; Marshall, L.Z.; et al. Real-world persistence and adherence to ...
org/doi/full/10.1056/NEJMoa2505669?log out=true. nejm.org. Orforglipron, an Oral Small- Molecule GLP-1 Receptor Agonist,. 母語ê/gǎi醫學 ?.
... 10.1056/NEJMoa2505669. Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Efficacy and Safety of Baxdrostat in Uncontrolled and ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
... 10.1056/NEJMoa2408954 ）。 豬腎異種移植：MGH 團隊在單一末期 ... org/10.1056/NEJMoa2505669 ）。 Ivermectin 防瘧：BOHEMIA 叢集隨機試驗 ...
... 10.1056/NEJMoa2408954 ）。 豬腎異種移植：MGH 團隊在單一末期 ... org/10.1056/NEJMoa2505669 ）。 Ivermectin 防瘧：BOHEMIA 叢集隨機試驗 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes • Efficacy and Safety of Baxdrostat in Uncontrolled ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056 ...
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
doi:10.1056/NEJMoa2505669 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #diabetes #GLP1 ...
Adults with obesity and type 2 diabetes who took orforglipron—an oral small-molecule GLP-1 receptor agonist—in addition to lifestyle changes ...
Rosenstock, J ∙ Hsia, S ∙ Ruiz, LN ∙ et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl ...
DOI:10.1056/NEJMoa2505669, https://www.nejm.org/doi/10.1056/NEJMoa2505669; Zhang, J., Wei, J., Lai, W., et al. (2025). Focus on Glucagon-like ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med 2025; DOI: 10.1056/NEJMoa2505669.
doi:10.1056/NEJMoa2505669. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Wharton S, Blevins T, Connery L, et al ...
Rosenstock J, Hsia S, Nevarez Ruiz L, et al. The New England Journal of Medicine. 2025;393(19):1860-1873. doi:10.1056/NEJMoa2505669. Daily Oral ...
org/doi/10.1056/NEJMoa2511774 Science often moves faster than ethics. ... org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Oral Semaglutide at a Dose of 25 mg in Adults with ...
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
... 10.1056/NEJMoa2505669. Glucagon-like peptide-1 (GLP-1) receptor agonists are well-established glucose-lowering medications for the ...
https://doi.org/10.1056/NEJMoa2505669 · Like · Reply. 1 Reaction. To view or add a comment, sign in. More Relevant Posts. The Sunrise Post. 52 ...
2025;doi:10.1056/NEJMoa2505669. Healio AI. Ask a clinical question and tap into Healio AI's knowledge base. PubMed, enrolling/recruiting ...
... online June 21. https://doi.org/10.1056/NEJMoa2505669 · Google Scholar. Article metrics. Recommend this journal to your librarian. Advertisement.
... 10.1056/NEJMoa2505669. Log ... #減重新藥 #Orforglipron #GLP1RA #肥胖治療 #糖尿病輔助治療 https://www.nejm. org/doi/abs/10.1056/NEJMoa2505669.
... #肥胖治療 #糖尿病輔助治療 https://www.nejm. org/doi/abs/10.1056/NEJMoa2505669. 林曉婷and 14 others · ? 15 · ? · ? 1. Recent posts. 肝炎 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes 2. Weekly Fixed-Dose Insulin Efsitora in Type 2 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity. N Engl J Med. 2025. doi: 10.1056/NEJMoa2511774; Wharton ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Jun 21. PMID: 40544435 ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes https://www.nejm.org/doi/10.1056/NEJMoa2505669 (6:06 ...
อ้างอิง: https://www.nejm. org/doi/full/10.1056/NEJMoa2505669 . #Orforglipron #เบาหวาน #ยาลดน้ำหนัก #หมอยาเพ้อเจ้อ ⚕️ · No photo ...
จากการศึกษา phase 3 ล่าสุด ใน new england journal "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes" .
DOI: 10.1056/NEJMoa2505669. American Diabetes Association. Standards of Care in Diabetes—2020 Abridged for Primary Care Providers ...
Orforglipron, an oral small-molecule glp-1 receptor agonist in early type 2 diabetes. Abstract presented at: American Diabetes Association's ...
doi:10.1056/NEJMoa2505669. Contributors. BT · By Brandon Twyford. Recommended For You. metto. Obesity · Does Delayed Gastric Emptying Influence ...
Read the articles: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes: https://lnkd.in/gp9Ru4KS Weekly ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type. MESSENGER. Orforglipron, an Oral Small- Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in ...
DOI: 10.1056/NEJMoa2505669. Journal information: New England Journal of Medicine. Key medical concepts. orforglipronObesityDiabetes Type 2 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine. June 21, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393:1065-1076. doi:10.1056 ...
doi:10.1056/NEJMoa2505669; Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 ...
... 10.1056/NEJMoa2505669 | Hyung Jin Choi. Log in. Facebook. No ... org/doi/full/10.1056/NEJMoa2505669. Jeongwon Park and 37 others · ? 38.
... 別忘了定期追蹤醫師Ref: DOI: 10.1056/NEJMoa2505669 #糖尿病#GLP1 #口服腸泌素#orforglipron #Rybelsus #減重#控糖#ADA2025. Log in · ?. 吳書婷醫師's ...
org/doi/full/10.1056/NEJMoa2502081 ； https://www.nejm. org/doi/full ... org/doi/full/10.1056/NEJMoa2505669. nejm.org. Coadministered ...
... las formulaciones inyectables. Referencia: – Rosenstock J, et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2505669".
林嘉俊醫師| 家醫•減重•糖尿病•疫苗(@drlimkc). 628 Views. https://www.nejm.org/doi/full/10.1056/NEJMoa2505669.
doi: 10.1056/NEJMoa2505669; Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile ...
N Engl J Med. 2025;doi:10.1056/NEJMoa2505669. Perspective. Back to Top. Amy Hess-Fischl, MS, RDN, LDN, ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in ...
... with placebo. https://www.nejm. org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others · 24.
org/doi/full/10.1056/NEJMoa2505669 ————————————————————————- Orforglipron คืออะไร? —————————————- เป็นยาในกลุ่ม GLP-1 receptor ...
ตัวนี้กำลังจะตามมานะครับ เบื้องหลังยาลดอ้วนสุดฮิตอย่าง Zepbound (ของ Eli Lilly) และ Wegovy (ของ Novo Nordisk) คือกลุ่มยา GLP-1 Agonist ...
... las formulaciones inyectables. Referencia: – Rosenstock J, et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2505669".
63 votes, 10 comments. Link to full trial data here: https://www.nejm.org/doi/full/10.1056/NEJMoa2505669 In the world of diabetes and GLP1 ...
٦٣ من الأصوات، ١٠ من التعليقات. لينك بيانات التجربة الكاملة هنا: https://www.nejm.org/doi/full/10.1056/NEJMoa2505669 في عالم أدوية السكر ...
org/doi/full/10.1056/NEJMoa2505669 #ADA2025 · No photo description available. มิก มิก มิก and 23 others. 24 reactions ·. 12 comments. ·. 3 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
▫️ACHIEVE-4: Orforglipron vs Ins glargina https://www.nejm.org/doi/pdf/10.1056/NEJMoa2505669. June 23, 2025 · semergengtdm's profile ...
▫️ACHIEVE-4: Orforglipron vs Ins glargina https://www.nejm.org/doi/pdf/10.1056/NEJMoa2505669. June 23, 2025 · semergengtdm's profile ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2511774; Wharton ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, Phase 3 trial data · r/FamilyMedicine - Orforglipron ...
อ้างอิง: https://www.nejm. org/doi/full/10.1056/NEJMoa2505669 . #Orforglipron #เบาหวาน #ยาลดน้ำหนัก #หมอยาเพ้อเจ้อ ⚕️ · No photo ...
DOI: 10.1056/NEJMoa2505669 • Aronne LJ, et al. ATTAIN‑MAINTAIN. Nature Medicine, 2026. DOI: 10.1038/s41591-026-04386-7. 1 hour ago · dr ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi: 10.1056 ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025, 393:1065-76. 10.1056 ...
D内
N
MM
KS
RL
H
GL
NO
EG
内J
S
L
PO
NP
MP
NP
DB
D
LI
DE
TB
JA
DV
H
SA
AS
KA
B
EA
EC
JF
MY
DK
S
IM
DJ
JT
ES
L
MM
M
JB
HH
AF
Tで
KN
BM
CS
WL
VZ
C
PM
PG
P食
DM
உவ
HS
AM
P
Y
VM
VP
RB
EG
RD
R
BM
BM
JM
HE
LC
L猫
N
BD
PN
RP
YM
PC
JA
JG
A
JE
TK
MA
NH
AR
M
ED
X
SI
FM
LO
GB
JA
LP
AA
DD
AE
JQ
CM
AS
CI
DN
FE
CM
PB
DD